search for: therapy

.... I'm trying to duplicate a case study example from my textbook [1]: > # Case Study 13.2.1, page 778 > cd <- c(8, 11, 9, 16, 24) > dp <- c(2, 1, 12, 11, 19) > lm <- c(-2, 0, 6, 2, 11) > table <- data.frame(Block=LETTERS[1:5], "Score changes"=c(cd, dp, lm), Therapy=rep(c("Contact Desensitisztion", "Demonstration Participation", "Live Modeling"), each=5)) > table Block Score.changes Therapy 1 A 8 Contact Desensitisztion 2 B 11 Contact Desensitisztion 3 C...

...ges for Markov models available in R. Apologies for now posting a code snippet, but I am looking for some guidance here. Please consider a set like the one below (which you can get with data<-read.csv('http://dl.dropboxusercontent.com/u/5685598/data_table.csv') ). ID therapy age1 age2 EFS 7308 ormo_lunga 78 84 73 7308 ormo_medio 78 84 73 7308 ormo_lunga 78 84 73 4902 chemio_lunga 46 56 120 4902 ormo_lunga 46 56 120 4902 ormo_lunga 46 56 120 4902 ormo_breve 46 56 120 4902 chemio_lunga 46 56 120...

Hi Folks: **Off Topic** Those interested in clinical trials may find the following of interest: http://www.nytimes.com/2010/09/19/health/research/19trial.html It concerns the ethicality of randomizing those with life-threatening disease to relatively ineffective SOC when new "biologically targeted" therapies "appear" to be more effective. While the context may be new, the

...CT OUTLINE Genomic alterations are major determinant of responses to (targeted) therapies in cancer. In fact, the best positive and negative predictors of responses to targeted therapies are alterations in kinases or their direct downstream effectors. To gain insight into resistance mechanisms to therapy and thus better tailor treatment, we are approaching this problem from two different angles. First, we have acquired large panels of human tumors, on which we are currently performing kinase exon sequencing. More specifically, we are performing sequencing on 1) 400 samples from the NEO-ALTTO study...

...argument to pass factor names to the variables 'group' and 'city'. In the interaction plot now the groups are referred to as '1', '2' and '3' and the citys are referred to '1', 2'. Hoewever, Id like to pass string character names to those ('Therapy 1, 'therapy 2 and therapy 3). I'd also like to pass string character names to the varibale 'city' ('Amsterdam', "Rotterdam', etc.) I'm a quite new user (since two weeks), and normally I can easily find the solution to my problems on the internet, but however...

...9;s post or just hit the delete button! The situation is that I have co-developed a "copyleft" self-report measure that adult, tabloid literate clients in psychological therapies can complete readily that gives reasonable indication of their state say at referral, assessment, start of therapy, during therapy, end of therapy, follow-up etc. It's part of a system we call CORE (Clinical Outcomes in Routine Evaluation). How it is used is up to practitioners as our aim is to persuade therapists that such data can be of use to them, not just to researchers. There is a linked thera...

Hi, I am doing a retrospective analysis on a cohort from a designed trial, and I am fitting the model fit<-glmD(survived ~ Covariate*Therapy + confounder,myDat,X=TRUE, Y=TRUE, family=binomial()) My covariate has three levels ("A","B" and "C") and therapy has two (treated and control), confounder is a continuous variable. Also patients were randomized to treatment in the trial, but Covariate is something t...

...t of 4 $ survobj : Surv [1:129, 1:2] 0.8925+ 1.8836+ 2.1191+ 5.3744+ 1.6099+ 5.2567 0.2081+ 0.2108+ 0.2683+ 0.4873+ ... ..- attr(*, "dimnames")=List of 2 .. ..$ : NULL .. ..$ : chr [1:2] "time" "status" ..- attr(*, "type")= chr "right" $ therapy : Factor w/ 2 levels "treatment1","treatment2": 1 1 1 1 1 1 1 2 2 1 ... $ ReceptorA: Factor w/ 2 levels "0","1": 1 2 2 2 1 2 2 2 2 1 ... $ ReceptorB: Factor w/ 2 levels "0","1": 1 2 1 1 2 1 1 1 1 1 ... But when I tried to fit a multiva...

...set to use sqlsever before) and attempted the import. I haven''t changed a thing in the schema.rb script and, even though I do have generated a migration, I think I don''t even need it and rake simply ignores it (or I guess it does). The rake script exits like this: C:\Lorenzo\therapy>rake db_schema_import (in C:/Lorenzo/therapy) rake aborted! undefined method `[]='' for #<Mysql> (See full trace by running task with --trace) Anybody knows what the story is? Thanks in advance, Lorenzo -- Posted via http://www.ruby-forum.com/.

...I wrote in R. It seems to work but the results are not the same. I don't know how to specify the class variable in R or specify the variance matrix. Can you please help me? Thanks Jurgen ## SAS: proc glimmix data=trend method=RSPL; class pid; model mdrfinal (event = '1') = time therapy comment / dist=binary link=logit solution cl; random intercept / subject=pid type=un; run; ## R: model_GLMM<- glmmPQL(mdrfinal ~ time + therapy + comment, data = data, family = binomial, random = ~1| time) summary(model_GLMM) -- View this message in context: http://r.789695.n4.nabble.com/c...

...) , rails once again showed its effectiveness. Last friday I read the news about a guy who sold a million pixels for 1$ each on his homepage. After slamming my head during half an hour for not having thought of it [1], I thought I''d better spend some time on a rails project, and more as a therapy than in the hope to become a millionair, I put http://milliondollarweek.com in place. It was a real pleasure to see the implementation progress that fast: design the database schema, generate scaffold, adapt the scaffold, add an engine for authentication. In less than 24 hours the infrastructure w...

Is there anything in the Puppet/Passenger setup process that edits httpd.conf and sets the User/Group running apache to "puppet" ? A master I set up several months ago is configured that way. I do not recall doing it. But then the high voltage electroshock therapy does have its side effects :) “Sometimes I think the surest sign that intelligent life exists elsewhere in the universe is that none of it has tried to contact us.” Bill Waterson (Calvin & Hobbes) -- You received this message because you are subscribed to the Google Groups "Puppet U...

Hello, I need help in performing a Van_der_Waerden normal scores test in R. I have two arrays of scores(final on therapy scores from drug and placebo) and want to use the normal scores procdeure to test for significance. (observations are unequal in number - due to dropouts). Could you please help me out with the coding or let me know if there is a package that can be used (for example, suppdist etc.) Thanks in...

...a problem with Sophos's firewall not R and I'm just reporting it here in case anyone else sees the same and finds this helpful. Thanks to the R team, yet again, for an amazing product! Chris -- Chris Evans <chris at psyctc.org> Skype: chris-psyctc Consultant Psychiatrist in Psychotherapy, Notts. PDD network; Trust Research Governance Lead and Clinical Director, Psychological Therapies Directorate in Local Services, Nottinghamshire NHS Trust; Professor, Psychotherapy, Nottingham University *If I am writing from one of those roles, it will be clear. Otherwise* *my views are my own...

...t of 4 $ survobj : Surv [1:129, 1:2] 0.8925+ 1.8836+ 2.1191+ 5.3744+ 1.6099+ 5.2567 0.2081+ 0.2108+ 0.2683+ 0.4873+ ... ..- attr(*, "dimnames")=List of 2 .. ..$ : NULL .. ..$ : chr [1:2] "time" "status" ..- attr(*, "type")= chr "right" $ therapy : Factor w/ 2 levels "treatment1","treatment2": 1 1 1 1 1 1 1 2 2 1 ... $ ReceptorA: Factor w/ 2 levels "0","1": 1 2 2 2 1 2 2 2 2 1 ... $ ReceptorB: Factor w/ 2 levels "0","1": 1 2 1 1 2 1 1 1 1 1 ... But when I tried to fit a multiva...

...of the current device. This can be done by pointing and clicking on the "history" tab of a graphics device in windows, but I would like to do this in a script. Best regards, Andy Andrew Hooker, Ph.D. Associate Professor of Pharmacometrics Div. of Pharmacokinetics and Drug Therapy Dept. of Pharmaceutical Biosciences Uppsala University Box 591, 751 24, Uppsala, Sweden Phone: +46 18 471 4355 Mobile: +46 701 679 048 <http://www.farmbio.uu.se/research.php?avd=5> www.farmbio.uu.se/research.php?avd=5 [[alternative HTML version deleted]]

...positve. ...", " ... Still need to order KRAS mutation testing. ... ", " ... Tumor is negative for KRAS mutation. ...", " ... Tumor is wild type. Patient is eligible to receive Eribtux. ...", " ... Will conduct KRAS mutation testing prior to initiation of therapy with Erbitux. ..." ), class = "factor")), .Names = c("profile_key", "encounter_date", "raw"), row.names = c(NA, -16L), class = "data.frame") The following code displays the results of so-called "simple" coding. #### Simple coding #...

...wise. There are 11 covariates, listed below, all of which are numerical variables. ```r library(aVirtualTwins) # Load data data(sepsis) # Format data vt.obj <- vt.data(dataset = sepsis, outcome.field = "survival", treatment.field = "THERAPY", interactions = TRUE) ## "1" will be the favorable outcome # view of data head(sepsis) ## survival THERAPY PRAPACHE AGE BLGCS ORGANNUM BLIL6 BLLPLAT ## 1 0 1 19 42.921 15 1 301.80 191.0000 ## 2 1 1 48 68.8...

...wise. There are 11 covariates, listed below, all of which are numerical variables. ```r library(aVirtualTwins) # Load data data(sepsis) # Format data vt.obj <- vt.data(dataset = sepsis, outcome.field = "survival", treatment.field = "THERAPY", interactions = TRUE) ## "1" will be the favorable outcome # view of data head(sepsis) ## survival THERAPY PRAPACHE AGE BLGCS ORGANNUM BLIL6 BLLPLAT ## 1 0 1 19 42.921 15 1 301.80 191.0000 ## 2 1 1 48 68.8...

...any in the world. Headquartered in Irvine, California, Edwards has more than 5,000 employees worldwide, selling medical technologies in more than 100 countries. Edwards Lifesciences leverages its research, design, development and marketing expertise through five main product categories: Heart Valve Therapy, Critical Care, Cardiac Surgery, Vascular Therapy, and Transcatheter Valve Interventions. For us, saving lives is not just a slogan; it's what we do. From developing devices that keep a heart pumping to creating new technologies which monitor vital signs in the critical care setting, we help e...